Venous thromboembolism (VTE) is the second leading cause of death and a major cause of morbidity in patients with cancer. Pharmacologic thromboprophylaxis is recommended in all hospitalized cancer patients without contraindications to anticoagulants. The role of thromboprophylaxis in outpatients undergoing chemotherapy is less certain because of the diversity of the tumor types and their associated risks of VTE and bleeding. Thromboprophylaxis should only be considered in patients at high risk for VTE. Cancer patients with a newly diagnosed VTE should be preferably treated with low-molecular-weight heparin for a minimum of 3-6 months. Treatment duration should be individualized based on the clinical status and stage of the cancer, the risk of recurrent VTE, the risk of bleeding, and personal preference of the patient. Further research is required to assess the role of the new oral anticoagulants (direct Xa and thrombin inhibitors) for this high-risk population.
Introduction
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE) are common in cancer patients. Patients with cancer have a fourfold increased risk of developing VTE when compared with the general population [Blom et al. 2005; Heit et al. 2002] . Systemic chemotherapy, cancer hormonal therapy and other supportive measures (e.g. erythropoietin stimulating agents) have been shown to increase that risk further [Bohlius et al. 2006; Blom et al. 2005 ]. More recently, anti-angiogenic agents (e.g. bevacizumab) and immunomodulatory agents (e.g. thalidomide and lenalidomide) have also been shown to increase the risk of VTE in patients with a variety of solid tumors (colorectal, breast, renal cell and non-small cell lung carcinoma [NSCLC] and multiple myeloma [MM] ) [Carrier et al. 2011; Nalluri et al. 2008 ]. Cancerassociated thrombosis can delay or interfere with anticancer therapy, precipitate or prolong hospitalization, and utilize scarce healthcare resources. Therefore, effective thromboprophylaxis and appropriate treatment of VTE are important strategies for minimizing morbidity and mortality for cancer patients and potentially reducing healthcare costs.
Cancer-associated thrombosis, death and prognosis
Thromboembolism is the second leading cause of death in patients with cancer ]. The annualized death rate for VTE in cancer patients is approximately 500 per 100,000 patients which is 47-fold higher than in the general population. VTE seems to lead to an increased mortality rate in both hospitalized and ambulatory cancer patients [Fotopoulou et al. 2008; Khorana et al. 2007a Khorana et al. , 2006 . A recent analysis of 1,824,316 patients including 1,015,598 cancer patients showed that mortality was significantly increased among patients who developed VTE as compared with those who did not (16.3% versus 6.3%; p < 0.0001) . Similarly, cancer patients with VTE hospitalized with febrile neutropenia were demonstrated to have greater in-hospital mortality compared with those without thrombosis [Khorana et al. 2006 ]. Finally, a significant decrease in overall survival was reported in a pooled analysis of 2743 women with ovarian cancer undergoing platinum paclitaxel-based chemotherapy following primary surgical resection (29.8 months in women with VTE versus 36.2 months without VTE; p ¼ 0.03) [Fotopoulou et al. 2008 ]. VTE appears to have an effect on both short-and long-term prognosis Sorensen et al. 2000] . A recent study has suggested that cancer-associated thrombosis was associated with early mortality in cancer patients undergoing chemotherapy. A total of 4458 patients with solid tumors or malignant lymphoma were followed for a median of 75 days. A total of 93 patients had a VTE at a median of 38 days following initiation of chemotherapy. Multivariate analyses showed that VTE was a significant predictor of early mortality (hazard ratio [HR] 4.5, 95% confidence interval [CI] 1. 61-12.53 ; p < 0.004) . Similarly, a Danish Cancer registry comparing 668 cancer patients with DVT with 5371 matched control cancer patients reported a significant reduction of the 1-year overall survival rates (12% versus 36%; p < 0.0001) and the mortality ratio for the entire follow-up period was 2.2 (95% CI 2.05-2.40) [Sorensen et al. 2000] . A more recently published study including 235,149 cancer patients from the California Cancer registry has also suggested that VTE was associated with a worse long-term prognosis in cancer patients. In that study, a total of 3775 (1.6%) of cancer patients were diagnosed with a VTE over a 2-year period. VTE was associated with an increased risk of mortality for all stages and cancer types except for regional and metastatic renal cancer with an overall HR of 3.7 (95% CI 1.3-14.4) ]. Although the effect of VTE on mortality in studies involving multiple sites might be partly attributed to the worse prognosis of more thrombogenic tumor types (e.g. pancreatic cancer) or the presence of a more advanced disease state (e.g. metastatic disease), numerous studies have assessed the association within specific tumor types, stage, or histology. A recent analysis of 108,255 patients with breast cancer demonstrated that VTE was a significant predictor of decreased 2-year survival (HR 2.3; 95% CI 2.1-2.6) and stratification by initial cancer stage showed that the effect was highest in patients with localized (HR 5.1; 95% CI 3.6-7.1) or regional stage (HR 3.5; 95% CI 2.5-4.8) cancer compared with patients with metastatic disease (HR 1.9; 95% CI 1.5-2.4) [Chew et al. 2007 ]. In a risk-adjusted model including 68,142 colorectal-cancer patients, VTE was also a significant predictor of death within 1 year of cancer diagnosis among patients with local (HR 1.8; 95% CI 1.4-2.3) or regional-stage disease (HR 1.5; 95% CI 1.3-1.8) but not among patients with metastatic disease (HR 1.1; 95% CI 1.0-1.2) [Alcalay et al. 2006 ]. Finally, another analysis of the California Cancer Registry assessing 91,933 patients with newly diagnosed lung cancer, the 1year and 2-year cumulative VTE incidences were 3.0% and 3.4%, respectively. Multivariate analyses showed that VTE was a significant predictor of death within 2 years independent of histology (non-small cell lung cancer or small cell lung cancer) [Chew et al. 2008] . Therefore, the association between VTE and increased mortality cannot be solely attributed to cancer types and staging. However, the association is likely multifactorial and might be a surrogate for adverse tumor biology leading to a worse prognosis. More research is needed to investigate the mechanism behind clinical hypercoagulable state and tumor biology.
Risk stratification for cancer-associated thrombosis
Given the high prevalence of VTE in cancer patients and its associated detrimental effect on mortality and morbidity, a risk assessment score to predict the development of cancer-associated thrombosis in cancer patients undergoing chemotherapy has been proposed. This risk assessment score was developed using the Awareness of Neutropenia in Chemotherapy Study registry using cancer patients who had completed at least one cycle of chemotherapy . Five predictive variables were identified to assess the risk of symptomatic VTE during the first cycle of chemotherapy: (1) site of cancer;
(2) platelet count; (3) hemoglobin level and or/ use of erythropoiesis-stimulating agents; (4) leukocytes counts; and (5) body mass index (Table 1) . A total of 27% of patients were stratified within the low-risk group in both derivation and validation cohorts whereas 13% and 11% were categorized in the high-risk group in the derivation and validation cohort, respectively. Rates of VTE in the derivation and validation cohorts were 0.8% and 0.3% in the low-risk group, 1.8% and 2% in the intermediate-risk group and 7.1% and 6.7% in the high-risk group, respectively ]. The Khorana's risk assessment score was recently validated ]. Incorporating additional variables including biomarkers (e.g. D-dimer, tissue factor, soluble P selectin, thrombin generation) has been proposed and seem to potentially improve the risk assessment score Zwicker et al. 2009] . A prospective and observational cohort study of 819 patients with newly diagnosed cancer or progression of disease after remission was conducted to assess an expanded version of Khorana's risk assessment score by incorporating two biomarkers (soluble P selectin and D-dimer). A total of 61 VTEs occurred over a median of 656 days. Rates of VTE in the original and expanded version of the risk assessment scores were 17.7% and 35% in the high-risk group, 9.6% and 10.3% in the intermediate-risk group and 1.5% and 1% in the low-risk group, respectively. The HR of patients with the highest compared with those with the lowest score was 25.9 (95% CI 8.0-84.6). However, only 4% (n ¼ 30) of the entire sample was classified within the highest-risk group. Although biomarkers are promising and seem to improve the risk stratification of VTE in cancer patients undergoing chemotherapy, it is important to recognize these assays are not uniformly standardized and different assays might not yield similar accuracy. Studies assessing the use of VTE risk assessment scores to determine the need for pharmacological thromboprophylaxis in ambulatory cancer patients undergoing chemotherapy are ongoing and might be able to provide clinicians with more insight to tailor the risk-benefit ratio of thromboprophylaxis in this high-risk population.
Prevention of cancer-associated thrombosis in medical patients
Hospitalized medically ill cancer patients Cancer patients who are hospitalized for medical problems have an increased risk of VTE. A large study using hospital discharge databases showed that up to 5.4% of patients requiring hospitalization for chemotherapy will develop thrombotic complications [Khorana et al. 2006 ]. Furthermore, the incidence of VTE is rising in the hospitalized oncology population [Khorana et al. 2006; Stein et al. 2006 ]. Unfortunately, data from large randomized trials assessing pharmacological thromboprophylaxis in hospitalized patients with cancer are not available and the risk-benefit ratio of thromboprophylaxis has never been formally studied in this population. Large randomized, doubleblind, placebo-controlled trials evaluating a lowmolecular-weight heparin (LMWH; enoxaparin 40 mg or dalteparin 5000 U daily) or fondaparinux (2.5 mg daily) in hospitalized medical patients have included approximately 5-15% of patients with a diagnosis of cancer [Francis, 2007; Cohen et al. 2006; Leizorovicz et al. 2004; Samama et al. 1999] . Therefore, it is probable that cancer patients would benefit from pharmacological prophylaxis [Francis, 2007] . A post hoc analysis of one of the trials has reported no difference between cancer patients receiving thromboprophylaxis and placebo [Alikhan et al. 2003 ]. The study sample was small and the analysis was underpowered. Consensus guidelines are supporting the use of pharmacological thromboprophylaxis [Geerts et al. 2008; Lyman et al. 2007b ]. However, compliance is poor in hospitalized cancer patients [Geerts et al. 2008; Amin et al. 2007; Lyman et al. 2007b] . A randomized controlled trial has recently showed that an electronic alert system was able to increase physician compliance in prescribing thromboprophylaxis and resulted in a significant reduction of symptomatic VTE by 41% [Kucher et al. 2005 ]. Computerized prompts have also been shown to increase compliance and decrease VTE specifically in hospitalized oncology patients [Candelario et al. 2010 ]. Hence, effective thromboprophylaxis in hospitalized cancer patients could have an important impact on overall survival.
Hospitalized medically ill cancer patients with a contraindication to pharmacological thromboprophylaxis should be considered for mechanical thromboprophylaxis. Intermittent pneumatic compression (IPC) devices and/or graduated compression stockings (GCSs) are reasonable alternatives. However, few studies have addressed the efficacy of such mechanical prophylactic devices in hospitalized cancer patients. A recent systematic review showed a lower crude cumulated DVT rate with IPC compared with GCSs in patients following abdominal surgery [Morris and Woodcock, 2010] . The use of mechanical thromboprophylaxis is limited by improper fit and patient's noncompliance. Furthermore, combination of pharmacological and mechanical thromboprophylaxis has shown a significantly decreased incidence of both symptomatic PE and DVT when compared with mechanical modalities alone [Kakkos et al. 2008] . Thus, once a patient's contraindication to thromboprophylaxis with an anticoagulant resolves, the addition of pharmacological thromboprophylaxis should be considered.
Outpatients undergoing chemotherapy
Several studies have assessed the use of LMWH or ultra-LMWH for thromboprophylaxis in outpatients undergoing chemotherapy (Table 2 ) [Agnelli et al. 2011 [Agnelli et al. , 2009 Haas et al. 2005; Maraveyas et al. 2011; Perry et al. 2010; Reiss et al. 2009 ]. Whereas some studies have showed a significant difference in overall or symptomatic VTE between the treatment groups, others have not. The CONKO-004 trial and the FRAGEM study have both showed a significant relative risk reduction of VTE in patients with advanced pancreatic adenocarcinoma [Maraveyas et al. 2011; Reiss et al. 2009 ]. The PROTECHT study has also shown that thromboprophylaxis using nadroparin significantly decreases the risk of venous and arterial thrombosis in patients with locally advanced or metastatic cancers [Agnelli et al. 2009 ]. More recently, the SAVE-ONCO trial evaluated the use of the ultra-LMWH semuloparin in patients with locally advanced or metastatic disease [Agnelli et al. 2011] . Semuloparin was shown to significantly decrease the risk of symptomatic VTE (HR 0.36; 95% CI 0.21-0.6) without increasing the risk of bleeding [Agnelli et al. 2011] . Although the PROTECHT and SAVE-ONCO have reported significant relative risk reduction in their respective primary efficacy outcome measure, the absolute risk reduction is modest at 1.8% and 2.2%, respectively. In contrast, the TOPIC 1 and 2 studies have failed to show any significant difference between the treatment groups in patients with advanced breast cancer and non-small cell lung cancer respectively [Haas et al. 2005] . Similarly, the PRODIGE study did not show any significance difference in symptomatic VTE in patients with grade III/IV malignant glioma receiving prophylactic doses of dalteparin [Perry et al. 2010 ]. However, the PRODIGE study was stopped prematurely (186 out of 512 required patients) as a result of expiration of the study drug. These conflicting results suggest that pharmacological thromboprophylaxis might be effective in preventing VTE in only certain types of tumors (e.g. advanced pancreatic adenocarcinoma) or patients with high-risk features. Hence, identifying high-risk cancer patients who would be more likely to potentially benefit from thromboprophylaxis remains an important and unresolved clinical question. Unfortunately, none of the previously discussed trials used a risk assessment score to stratify patients according to their underlying risk of VTE. Finally, the incidence of bleeding episodes observed in the control groups varied considerably amongst the different studies suggesting that the risk-benefit ratio of thromboprophylaxis might vary for different tumor sites and stages [Kuderer et al. 2009 ]. Consensus guidelines from the ASCO and ACCP are currently not recommending routine thromboprophylaxis in ambulatory cancer patients undergoing chemotherapy [Geerts et al. 2008; Amin et al. 2007 ]. However, the most recent version of the NCCN guidelines suggest to consider using thromboprophylaxis in cancer patients with additional risk factors (i.e. high-risk tumor site, high platelet count, low hemoglobin or use of erythropoietin agents, high BMI, etc.).
Pharmacological thromboprophylaxis should be considered in patients with multiple myeloma who are receiving thalidomide-or lenalidomidebased chemotherapy. Aspirin, LMWH or warfarin may be effective agents in reducing symptomatic VTE [Carrier et al. 2011] . Given the high incidence of VTE specifically and the absence of level 1 data, randomized-controlled Unfortunately, there was insufficient data to report the risk of recurrent VTE per tumor type or histology. A prospectively cohort study of patients with DVT managed with warfarin has reported a higher hazard ratio for recurrent VTE in patients with lung (HR 6.9; 95% CI 3.0-15.9) and colorectal cancer (HR 5.1; 95% CI 2.3-11.3) [Prandoni et al. 2002] . DVT in women with breast cancer was associated with a lower risk of recurrence (HR 0.7; 95% CI 0.1-4.9) [Chew et al. 2007; Prandoni et al. 2002] . In a recent registry study including 2474 women with cancer-associated VTE, fatal recurrent PE within 30 days of follow up was more common in women with breast, colorectal, lung or pancreatic cancer [Trujillo-Santos et al. 2011 ]. It appears that some cancer types are associated with a greater probability of recurrence; however, there is insufficient data to produce any tailored therapeutic management at present. Further studies identifying risk factors for recurrent VTE in patients with cancer-associated thrombosis are required.
Risk of bleeding in cancer patients
Patients with cancer have a higher risk of bleeding while treated with anticoagulant therapy than those without cancer. A retrospective-population study from 1987 from -1989 from [Gitter et al. 1995 reported cumulative incidences of major hemorrhage at 12 and 24 months of 5.3% and 10.6%, respectively, among patients with treated with warfarin. Malignant disease was associated with major hemorrhage in all patients regardless of indication for anticoagulation. A prospectively cohort study of patients with DVT managed with warfarin has reported a rate of major bleeding episodes of 15.7/100 patient-years in cancer patients compared with 8.6/100 patientyears in noncancer patient [Prandoni et al. 2002] . The incidence of bleeding correlated with cancer stage. Similarly, a post hoc analysis of 1303 patients enrolled into two multicenter randomized-controlled clinical trials on the initial treatment of VTE showed that the rates of bleeding on warfarin was 13.3/100 patient-years (95% CI 5.4-27.5) and 2.1/100 patient-years (95% CI 0.7-5.0) for patients with and without cancer, respectively [Hutten et al. 2000 ]. Finally, an analysis of the international RIETE registry [Prandoni et al. 2010] shows that 36% of patients who had a major bleeding complication during treatment of VTE had cancer versus 20% of those who did not have a bleeding complication. Bleeding was fatal in 25% of cases; however, even after survival of the bleeding episode, these patients remained more likely to die in the 3 months after diagnosis of VTE. In contrast to these older trials, the more recent Swiss registry [Spirk et al. 2011 ] recorded 30-day bleeding rates of 7.2% and 6.0% in cancer and noncancer patients treated for VTE. However, the treatment regimens for patients with cancer and without cancer were different (i.e. more LMWH use in patients with cancer) Therefore, it is clear that patients with both cancer and VTE are at a higher risk of bleeding complications than those who do not have cancer. Furthermore, those who have a major bleeding episode are more likely to die either from the bleed, or following recovery from the bleed.
Initial anticoagulant therapy for cancer-associated thrombosis LMWH is the preferred approach for the initial 5-10 days of anticoagulant treatment . A recent Cochrane review [Akl et al. 2011] analyzed 16 randomized-controlled trials comparing treatments for the initial anticoagulation of cancer patients during the first week after diagnosis of acute VTE. Eleven studies compared initial treatment with unfractionated intravenous heparin (UFH) with LMWH. The pooled analysis showed a statistically significant mortality reduction at 3 months in patients treated with LMWH compared with those treated with UFH (RR 0.71; 95% CI 0.52-0.98). The pooled analysis for recurrent VTE did not show a significant advantage of LMWH over UFH (RR 0.78; 95% CI 0.29-2.08). No difference was found between fondaparinux and heparin, or between tinzaparin and dalteparin.
Long-term anticoagulant therapy for cancer-associated thrombosis As discussed above, cancer patients with VTE are more likely to have recurrent VTE or major bleeding episodes while on long-term anticoagulant therapy using warfarin. Cancer patients receiving warfarin therapy are less likely to stay in the therapeutic international normalized ratio (INR) range [Rose et al. 2007; Hutten et al. 2000 ] than VTE patients without cancer. Furthermore, cancer patients are more likely to have recurrent VTE when subtherapeutic (INR < 2.0) on warfarin therapy as compared with noncancer patients (estimated excess risk of recurrence 35 versus 9/100 patients-years) [Rose et al. 2007; Hutten et al. 2000 ].
Studies have compared the rate of recurrent VTE, bleeding and death in cancer patients treated with warfarin or LMWH (Table 3) . Compared with warfarin, LMWH treatment results in fewer episodes of VTE recurrence. The CLOT study [Lee et al. 2003 ] compared long-term anticoagulant therapy using dalteparin with warfarin for cancer-associated thrombosis.
Patients receiving dalteparin received 200 U/kg once per day for the first month followed by 150 U/kg for the following 5 months. The trial showed a relative risk reduction of 52% in symptomatic VTE at 6 months in patients receiving long-term anticoagulant therapy with dalteparin (p ¼ 0.002) [Lee et al. 2003 ]. There were no differences in the rates of bleeding episodes (major and any bleeding episodes) or death between the two groups. In the LITE study, cancer patients randomized to LMWH received therapeutic doses of tinzaparin (175 U/Kg once per day) for the 3-month treatment period. Although a significant difference in recurrent VTE between the two groups was observed at 12 months, there was no difference detected after the 3-month study treatment of LMWH [Hull et al. 2006 ].
A study randomizing patients with cancer-associated thrombosis to receive either therapeutic doses of tinzaparin for 6 months or warfarin is currently underway. Finally two small trials have assessed the use of enoxaparin as longterm anticoagulant therapy [Deitcher et al. 2006; Meyer et al. 2002] . Both trials have shown no difference in the rates of recurrent VTE but they were underpowered to detect a significant difference. A Cochrane review [Akl et al. 2008] reported a pooled hazard ratio for recurrent VTE of 0.47 (95% CI 0.32-0.71) favoring LMWH, but no difference on overall mortality rate, HR 0.96 (95% CI 0.81-1.14). There was no statistical difference between the incidence of bleeding events or thrombocytopenic episodes.
The evidence suggests that LMWH therapy is superior to warfarin therapy for long-term anticoagulation therapy for cancer-associated thrombosis in terms of preventing VTE recurrences ]. The more predictable dose response obtained with LMWH compared with warfarin, can partly be explained by administration via the subcutaneous route and independence from dietary vitamin K intake. This makes the treatment more effective than warfarin during periods of nausea, vomiting, diarrhea and poor oral intake. Furthermore, the dose of LMWH seldom requires alteration which may improve patient compliance in comparison with warfarin which necessitates regular INR checks and dose alterations. Cessation of anticoagulation prior to surgical intervention is less complicated with LMWH which may further reduce the incidence of recurrent VTE.
It is unclear whether LMWH should be given at a therapeutic dose for the entire duration of the anticoagulation period or not. As discussed above, the CLOT study treated patients with therapeutic doses of dalteparin for the first month, followed by 75-80% therapeutic dose for the following 5 months [Lee et al. 2003 ]. However, other trials have given therapeutic doses of LMWH (tinzaparin and enoxaparin) for a total duration of 3 months [Hull et al. 2006; Meyer et al. 2002] . It is difficult to compare the individual study outcomes given the differences in the follow-up period and relatively small sample sizes of the studies, and relate these outcomes to drug dosing alone. One prospective cohort study reported outcomes of 203 consecutive patients with cancer-associated thrombosis treated with 10,000 U of dalteparin once per day for 3 months regardless of weight [Monreal et al. 2004 ]. All patients had metastatic cancer. A total of 21 patients (10%) had recurrence within 3 months, 11 (5%) had a major bleed and 65 (32%) died within 3 months. As yet, there have been no studies comparing doses of LMWH for cancer-associated thrombosis. Given the heightened risk of recurrent VTE and major bleeding episodes in cancer patients with VTE, dose reduction of the LMWH following the first month of treatment should be made on an individual patient basis. A trial using 6 months of full dose tinzaparin treatment versus warfarin in cancer patients with VTE is currently recruiting, and may provide more insight on this important clinical issue.
There is a dearth of evidence to guide physicians when treating VTE in the presence of chemotherapy induced thrombocytopenia. Several cancerassociated thrombosis studies have used dose reduction protocols during episodes of severe thrombocytopenia. The CLOT study [Lee et al. 2003 ] withheld LMWH if the platelet count dropped below 50,000, and reduced the dose of LMWH with platelet counts of 50,000-100,000.
Of the 19 patients treated with dalteparin who had a major bleed, two were thrombocytopenic. In contrast, Monreal and colleagues continued dalteparin therapy at a dose of 5000 U with a platelet count <50,000 and 2500 U if the platelets dropped below 10,000 [Monreal et al. 2004] .
Thrombocytopenia was associated with 7/16 patients with minor bleeding and 0/11 patients with major bleeding. Although it is impossible to quantify the risk of bleeding in patients with chemotherapy-induced thrombocytopenia it appears appropriate to reduce the dose of LMWH with platelet counts of 50,000 or less.
In the setting of acute VTE, consideration should be given to temporary inferior vena cava filter insertion to protect against further pulmonary embolism. The decision to omit anticoagulation should be made on an individual patient basis. 
Treatment of recurrent VTE
There is little published research to guide the approach to cancer patients who have been diagnosed with a recurrent VTE while on anticoagulant therapy for cancer-associated thrombosis. There is no evidence supporting the use of temporary inferior vena cava (IVC) filters in cancer patients. One open-label, randomizedcontrolled trial has studied the efficacy of inserting a permanent IVC filter in addition to standard anticoagulation for preventing VTE recurrence in patients with acute VTE [PREPICT Study, 2005] . The study reported a significant reduction in PE (HR 0.37; 95% CI 0.17-0.79) at 8-year follow up in patients with a permanent IVC filter. However, there was no reduction in overall mortality and an increased incidence of DVT was demonstrated in the IVC filter group [PREPICT Study, 2005] . A retrospective cohort study has also reported a high rate of DVT (32%) in cancer patients with IVC filters [Elting et al. 2004] . Therefore, IVC filters do not seem to provide any advantage to VTE patients receiving anticoagulation. Given the absence of survival advantage with permanent IVC filter insertion in patient receiving anticoagulation, the lack of safety data using the different types of temporary IVC filter and the increased risk of DVT in cancer patients with IVC, their use should be kept for patients with contraindications to anticoagulation. A retrospective cohort of 70 cancer patients with recurrent VTE while on LMWH reported 3-month follow-up results using dose escalation of LMWH [Carrier et al. 2009 ]. Patients with recurrent VTE had their dose increased by 20-25% for 4-6 weeks. During 3-month follow up, 9% had a second recurrent VTE and 4% developed a bleeding complication. A recent narrative review recommends dose escalation of LMWH by 20-25% in cancer patients with recurrent VTE while on LMWH [Lee, 2010] . Clinical evaluation should be performed after 5-7 days. If the patient has no clinical improvement, clinicians should aim for a peak anti-Xa level of 1.6-2.0 U/ml for once-daily LMWH and 0.8-1.0 U/ml for twicedaily dosing [Lee, 2010] . Cancer patients with recurrent VTE while on therapeutic warfarin (INR 2.0-3.0) should be switched to therapeutic levels LMWH with clinical reassessment within 5-7 days.
Conclusion VTE is associated with increased morbidity and mortality in cancer patients. All cancer patients admitted to hospital should be evaluated to receive pharmacological thromboprophylaxis. Despite the recent clinical trials, more research is required to evaluate the risk-benefit ratio of thromboprophylaxis in ambulatory cancer patients undergoing chemotherapy. The best evidence for treatment at present time suggests that commencing initial treatment with LMWH is superior to UFH and long-term anticoagulation should preferably be done using LMWH rather than warfarin for up to 6 months. All cancer patients should have an assessment of their risk of VTE recurrence as well as their risk of bleeding on anticoagulation. The total length of anticoagulation should be tailored to each individual patient. Dose escalation of LMWH seems effective and safe for cancer patients with recurrent VTE despite anticoagulation. IVC filter insertion should be reserved for cancer patients with contraindication to anticoagulant therapy.
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